2003
DOI: 10.1016/s0735-1097(03)80928-2
|View full text |Cite
|
Sign up to set email alerts
|

Volumeric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: Results of the DANTE randomized trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0
3

Year Published

2005
2005
2013
2013

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
(11 citation statements)
references
References 0 publications
0
8
0
3
Order By: Relevance
“…The volume (cubic millimeters) of the vessel, lumen and plaque were obtained and calculated as previously described. 15 Each measured volume was normalized to the examined segment length (cubic millimeters per millimeter) to compensate for the difference in examined vessel segment length in study patients. A plaque index was calculated as: (plaque volume/vessel volume) ϫ 100%.…”
Section: Methodsmentioning
confidence: 99%
“…The volume (cubic millimeters) of the vessel, lumen and plaque were obtained and calculated as previously described. 15 Each measured volume was normalized to the examined segment length (cubic millimeters per millimeter) to compensate for the difference in examined vessel segment length in study patients. A plaque index was calculated as: (plaque volume/vessel volume) ϫ 100%.…”
Section: Methodsmentioning
confidence: 99%
“…Off-line volumetric analysis of the 3D IVUS and VH-IVUS data was performed by 2 experienced operators blinded to clinical findings. Plaque volume (PV) was calculated as previously described 21 and normalized to the examined segment length (PV/SL mm 3 /mm). A plaque index (PI) was calculated as plaque volume/vessel volume ϫ 100%.…”
Section: Patient Populationmentioning
confidence: 99%
“…Safety. Major bleeding was reported in all but 7 trials (27)(28)(29)(30)(32)(33)(34). The incidence of major bleeding was 1.2% with GPI versus 0.9% with control (RR: 1.37, 95% CI: 0.83 to 2.25, p ϭ 0.22) (Fig.…”
Section: Resultsmentioning
confidence: 96%
“…1, Table 1) (10,11,(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40). The studies examined a variety of clinical outcomes, including 7 that used a nonclinical primary outcome (Table 2) (23,24,26,27,30,32,34). Details of GPI administration and adjuvant medications are listed in Table 3.…”
Section: Resultsmentioning
confidence: 99%